Lancet Public Health
Feb 2022 Volume 7 Number 2 e93-e194
https://www.thelancet.com/journals/lanpub/issue/current

Articles
The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study
Sébastien Morin, Hannah Barron Moak, Oliver Bubb-Humfryes, Christian von Drehle, Jeffrey V Lazarus,
Esteban Burrone
Non-exclusive voluntary licensing that is access-oriented has been suggested as an option to increase access to medicines to address the COVID-19 pandemic. To date, there has been little research on the effect of licensing, mainly focused on economic and supply chain considerations, and not on the benefits in terms of health outcomes. We aimed to study the economic and health effect of voluntary licensing for medicines for HIV and hepatitis C virus (HCV) in low-income and middle-income countries (LMICs).

Lancet Respiratory Medicine
Feb 2022 Volume 10 Number 2 p121-220, e11-e24
https://www.thelancet.com/journals/lanres/issue/current

Articles
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
Aurélien Mazeraud,et al.

Lancet Respiratory Medicine
Feb 2022 Volume 10 Number 2 p121-220, e11-e24
https://www.thelancet.com/journals/lanres/issue/current

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Seth Toback, et al. on behalf of the 2019nCoV-302 Study Group

Nature
Volume 602 Issue 7895, 3 February 2022
https://www.nature.com/nature/volumes/601/issues/7894

Editorial | 01 February 2022
The WHO deserves more money for its core mission — and more respect
After decades of neglect, the World Health Organization needs to be properly funded. The United States is — wrongly — opposing a new funding plan. Other nations shouldn’t wait to adopt it.

Nature Reviews Drug Discovery
Volume 21 Issue 2, February 2022
https://www.nature.com/nrd/volumes/21/issues/2

Comment | 07 December 2021
Choosing drugs for UK COVID-19 treatment trials
In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results. A similar approach could be used for non-communicable diseases where treatment advances have been limited.
Patrick F. Chinnery, Marion Bonnet, Tao You

New England Journal of Medicine
February 3, 2022 Vol. 386 No. 5
https://www.nejm.org/toc/nejm/medical-journal

Perspective
Trade-offs and Policy Options — Using Insights from Economics to Inform Public Health Policy T. Green and A.S. Venkataramani

Pediatrics
Volume 149, Issue 2, February 1, 2022
https://pediatrics.aappublications.org/

Articles
Human Milk SARS-CoV-2 Antibodies up to 6 Months After Vaccination
Stephanie E. Perez, BS; Luis Diego Luna Centeno, BA; Wesley A. Cheng, BS; Carolyn Jennifer Marentes Ruiz, MD; Yesun Lee, PhD …

Pediatrics
Volume 149, Issue 2, February 1, 2022
https://pediatrics.aappublications.org/

Vaccine Administration in Children’s Hospitals
Mersine A. Bryan, MD, MPH; Annika M. Hofstetter, MD, PhD, MPH; Douglas J. Opel, MD, MPH; Tamara D. Simon, MD, MSPH

Pediatrics
Volume 149, Issue 2, February 1, 2022
https://pediatrics.aappublications.org/

Ethics Rounds
Off-Label Prescription of COVID-19 Vaccines in Children: Clinical, Ethical, and Legal Issues
Jennifer E. deSante-Bertkau, MD, MBE; Timothy K. Knilans, MD; Govind Persad, JD, PhD; Patricia J. Zettler, JD; Holly Fernandez Lynch, JD, MBE …
Abstract
The US Food and Drug Administration (FDA) approval of the biologics license application for the Pfizer-BioNTech coronavirus disease 2019 vaccine (Comirnaty) on August 23, 2021, opened the door to the off-label vaccination of children younger than the age range currently covered by either the biologics license application (16 years old and older) or the emergency use authorization (12 to 15 years old). Although prescribing medications at doses, for conditions, or in populations other than those approved by the FDA is generally legal and is common in pediatrics, the FDA, the Centers for Disease Control and Prevention, and the American Academy of Pediatrics have recommended against off-label prescription of the coronavirus disease 2019 vaccine. Several commentaries consider a case in which parents ask their child’s pediatrician to prescribe the vaccine for their 11-year-old with special health care needs before approval or authorization in her age group. The first commentary considers the potential benefits and risks to the patient, as well as to the family, the provider, and society, emphasizing the unknown risks in younger patients and the need for adequate informed consent. The second commentary describes an algorithm and principles for evaluating off-label prescribing and argues that the current benefits of prescribing Comirnaty off label to children <12 do not outweigh the risks. The third commentary addresses ethical and legal issues, ultimately calling on federal agencies to remove legal barriers to making the vaccine available to children in age groups that currently lack authorization.

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

Research Article
Acceptance rate and risk perception towards the COVID-19 vaccine in Botswana
Lebapotswe B. Tlale, Lesego Gabaitiri, Lorato K. Totolo, Gomolemo Smith, Orapeleng Puswane-Katse, Eunice Ramonna, Basego Mothowaeng, John Tlhakanelo, Tiny Masupe, Goabaone Rankgoane-Pono, John Irige, Faith Mafa, Samuel Kolane
Research Article | published 04 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263375

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

Narratives and counter-narratives in religious responses to COVID-19: A computational text analysis
Ellen Idler, John A. Bernau, Dimitrios Zaras
Research Article | published 03 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0262905

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

People’s perceptions of, willingness-to-take preventive remedies and their willingness-to-vaccinate during times of heightened health threats
Angela Bearth, Anne Berthold, Michael Siegrist
Research Article | published 02 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263351

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

Comparing the impact of vaccination strategies on the spread of COVID-19, including a novel household-targeted vaccination strategy
André Voigt, Stig Omholt, Eivind Almaas
Research Article | published 02 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0263155

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

Compounding inequalities: Adolescent psychosocial wellbeing and resilience among refugee and host communities in Jordan during the COVID-19 pandemic
Nicola Jones, Sarah Baird, Bassam Abu Hamad, Zulfiqar A. Bhutta, Erin Oakley, Manisha Shah, Jude Sajdi, Kathryn M. Yount
Research Article | published 02 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261773

PLoS One
http://www.plosone.org/
[Accessed 05 Feb 2022]

mRNA Covid-19 vaccines in pregnancy: A systematic review
Nando Reza Pratama, Ifan Ali Wafa, David Setyo Budi, Manesha Putra, Manggala Pasca Wardhana, Citrawati Dyah Kencono Wungu
Research Article | published 02 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0261350

PNAS – Proceedings of the National Academy of Sciences of the United States
January 11, 2022; vol. 119 no. 2
https://www.pnas.org/content/119/2

Applied Mathematics
Open Access
Modeling for COVID-19 college reopening decisions: Cornell, a case study
Peter I. Frazier, J. Massey Cashore, Ning Duan, Shane G. Henderson, Alyf Janmohamed, Brian Liu, David B. Shmoys, Jiayue Wan, and Yujia Zhang
PNAS January 11, 2022 119 (2) e2112532119; https://doi.org/10.1073/pnas.2112532119

PNAS – Proceedings of the National Academy of Sciences of the United States
January 11, 2022; vol. 119 no. 2
https://www.pnas.org/content/119/2

Social Sciences
Open Access
Intersectional inequalities in science
Diego Kozlowski, Vincent Larivière, Cassidy R. Sugimoto, and Thema Monroe-White
PNAS January 11, 2022 119 (2) e2113067119; https://doi.org/10.1073/pnas.2113067119
Significance
The US scientific workforce is not representative of the population. Barriers to entry and participation have been well-studied; however, few have examined the effect of these disparities on the advancement of science. Furthermore, most studies have looked at either race or gender, failing to account for the intersection of these variables. Our analysis utilizes millions of scientific papers to study the relationship between scientists and the science they produce. We find a strong relationship between the characteristics of scientists and their research topics, suggesting that diversity changes the scientific portfolio with consequences for career advancement for minoritized individuals. Science policies should consider this relationship to increase equitable participation in the scientific workforce and thereby improve the robustness of science.

Preventive Medicine
Volume 155 February 2022
https://www.sciencedirect.com/journal/preventive-medicine/vol/155/suppl/C

Research article Full text access
Repercussions of the COVID-19 pandemic on preventive health services in Brazil
Mayra Monteiro de Oliveira, Trevon L. Fuller, Claudia R. Gabaglia, Mary Catherine Cambou, … Karin Nielsen-Saines
Article 106914

Preventive Medicine
Volume 155 February 2022
https://www.sciencedirect.com/journal/preventive-medicine/vol/155/suppl/C

Research article Full text access
Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel
Yaki Saciuk, Jennifer Kertes, Micha Mandel, Beatriz Hemo, … Anat Ekka Zohar
Article 106947

Public Health
Volume 203 Pages 1-130 (February 2022)
https://www.sciencedirect.com/journal/public-health/vol/203/suppl/C

Research article Full text access
ANTi-Vax: a novel Twitter dataset for COVID-19 vaccine misinformation detection
K. Hayawi, S. Shahriar, M.A. Serhani, I. Taleb, S.S. Mathew
Pages 23-30

Public Health
Volume 203 Pages 1-130 (February 2022)
https://www.sciencedirect.com/journal/public-health/vol/203/suppl/C

Research article Full text access
Investigating the association between COVID-19 vaccination and care home outbreak frequency and duration
D.T. Bradley, S. Murphy, P. McWilliams, S. Arnold, … D. O’Reilly
Pages 110-115

Science
Volume 375| Issue 6580| 4 Feb 2022
https://www.science.org/toc/science/current

Policy Forum
How NFTs could transform health information exchange
BY Kristin Kostick-Quenet, et al.
03 Feb 2022: 500-502
Can patients regain control over their health information?
Abstract
Personal (sometimes called “protected”) health information (PHI) is highly valued (¹) and will become centrally important as big data and machine learning move to the forefront of health care and translational research. The current health information exchange (HIE) market is dominated by commercial and (to a lesser extent) not-for-profit entities and typically excludes patients. This can serve to undermine trust and create incentives for sharing data (²). Patients have limited agency in deciding which of their data is shared, with whom, and under what conditions. Within this context, new forms of digital ownership can inspire a digital marketplace for patient-controlled health data. We argue that nonfungible tokens (NFTs) or NFT-like frameworks can help incentivize a more democratized, transparent, and efficient system for HIE in which patients participate in decisions about how and with whom their PHI is shared.

Science Translational Medicine
Volume 14| Issue 630| 2 Feb 2022
https://www.science.org/toc/stm/current

Research Articles
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
BY Baoling Ying, et al
02 Feb 2022
Open Access
mRNA-1273–based vaccines protect against historical and variant SARS-CoV-2 strains in 129S2 and K18-hACE2 mice.
Abstract
Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevent COVID-19, the emergence of new viral variants jeopardizes their efficacy. Here, we assessed the immunogenicity and protective …

Vaccine
Volume 40, Issue 3 Pages 397-554 (24 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/3

Discussion Abstract only
The polio vaccination story of Pakistan
Shabina Rahim, Zubair Ahmad, Jamshid Abdul-Ghafar
Pages 397-402

Vaccine
Volume 40, Issue 3 Pages 397-554 (24 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/3

Discussion Full text access
On the rise of the new B.1.1.529 variant: Five dimensions of access to a COVID-19 vaccine
Xiang Chen, Hui Wang
Pages 403-405

Vaccine
Volume 40, Issue 3 Pages 397-554 (24 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/3

Research article Abstract only
Impact of an accelerated measles-mumps-rubella (MMR) vaccine schedule on vaccine coverage: An ecological study among London children, 2012–2018
Joanne Lacy, Elise Tessier, Nick Andrews, Joanne White, … Michael Edelstein
Pages 444-449

Vaccine
Volume 40, Issue 3 Pages 397-554 (24 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/3

Research article Abstract only
Socioeconomic disadvantage and human papillomavirus (HPV) vaccination uptake
Shaheen Kurani, Kathy L. MacLaughlin, Robert M. Jacobson, Jennifer L. St. Sauver, … Lila J. Finney Rutten
Pages 471-476

Vaccine
Volume 40, Issue 3 Pages 397-554 (24 January 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/3

Research article Open access
COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers
Karen Lutrick, Holly Groom, Ashley L. Fowlkes, Kimberly D Groover, … Sarang Yoon
Pages 494-502

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 05 Feb 2022]

Research Article metrics AWAITING PEER REVIEW
Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative [version 1; peer review: awaiting peer review]
Kimberly M. Thompson, Dominika A. Kalkowska, Kamran Badizadegan
Peer Reviewers Invited
Funder
Bill and Melinda Gates Foundation
PUBLISHED 03 Feb 2022
Abstract
Background: Investments made by countries and donors to support polio eradication and the Global Polio Eradication Initiative (GPEI) over the past 35 years provided financial support for significant health interventions beyond the prevention of polio. Prior economic analyses that sought to quantify the economic benefits of some interventions encountered insufficient data and evidence associated with non-polio-specific activities. The 2022-2026 GPEI Strategic Plan explicitly identified integration and gender equity as funded mandates that must move forward in parallel with polio eradication, but these goals remain vaguely defined from a health economic perspective.
Methods: To ensure unambiguous and full accounting for all financial investments in the GPEI, polio eradication, and other desirable objectives, we identify the health economic analysis methods and inputs needed to ensure transparent financial accountability and cost-effective use of funds.
Results: Sufficient inputs and methods exist to characterize the health and economic benefits of polio-specific activities, but we identified the need for additional information and method development for some non-polio-specific and cost-sharing activities. Donors who seek to support non-polio-specific objectives as part of the GPEI may want to provide dedicated support financing for which it may be difficult to apply typical health economic criteria and to expect net health and/or net economic benefits.
Conclusions: Given the mixture of funding sources provided to the GPEI, which includes support by governments and private donors, we recommend that the GPEI separately account for financial needs that represent necessities for polio eradication from those used for other stated objectives. An added layer of specificity that identifies all funds according to each activity, the accountable party and/or parties, and the associated measurable health or other outcome(s), will enable improved health economic analyses and reporting to donors who seek to track returns on their investments.

Open Letter metrics
Revised
How modelling can help steer the course set by the World Health Organization 2021-2030 roadmap on neglected tropical diseases [version 2; peer review: 2 approved]
Jessica Clark, Wilma A. Stolk, María-Gloria Basáñez, Luc E. Coffeng, Zulma M. Cucunubá, Matthew A. Dixon, Louise Dyson, Katie Hampson, Michael Marks, Graham F. Medley, Timothy M. Pollington, Joaquin M. Prada, Kat S. Rock, Henrik Salje, Jaspreet Toor, T. Déirdre Hollingsworth
Peer Reviewers Angus McLure; Margaret C. Baker
Funders
Bill and Melinda Gates Foundation
UK Foreign, Commonwealth & Development Office
European and Developing Countries Clinical Trials Partnership (EDCTP2) programme
MRC Centre for Global Infectious Disease Analysis
UK Department for International Development
UK Medical Research Council
LATEST VERSION PUBLISHED 02 Feb 2022

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

Measles incidence in South Africa: a six-year review, 2015 – 2020
Mukhlid Yousif, Heather Hong, Susan Malfeld, Sheilagh Smit, Lillian Makhathin, Tshepo Motsamai, Dipolelo Tselana, Morubula Manamela, Mercy Kamupira, Elizabeth Maseti, Kennedy Otwombe, Kerrigan McCarthy, Melinda Suchard
medRxiv 2022.02.03.22270382; doi: https://doi.org/10.1101/2022.02.03.22270382

Transparency and reporting characteristics of COVID-19 randomized controlled trials.
Philipp Kapp, Laura Esmail, Lina Ghosn, Philippe Ravaud, Isabelle Boutron
medRxiv 2022.02.03.22270357; doi: https://doi.org/10.1101/2022.02.03.22270357

Effectiveness of the inactivated COVID-19 vaccine (CoronaVac) in adult population in Indonesia
Anton Suryatma, Raras Anasi, Miko Hananto, Asep Hermawan, Ririn Ramadhany, Irene Lorinda Indalao, Agustiningsih Agustiningsih, Ely Hujjatul Fikriyah, Teti Tejayanti, Rustika Rustika, Kristina Lumban Tobing, Ketut Suarjaya, I Wayan Widia, Pandji Wibawa Dhewantara
medRxiv 2022.02.02.22270351; doi: https://doi.org/10.1101/2022.02.02.22270351

Equitable COVID-19 vaccine prioritization: front-line workers or 65-74 year olds?
Eva Rumpler, Justin M Feldman, Mary T Bassett, Marc Lipsitch
medRxiv 2022.02.03.22270414; doi: https://doi.org/10.1101/2022.02.03.22270414

High Burden of COVID-19 among Unvaccinated Law Enforcement Officers and Firefighters
Alberto J. Caban-Martinez, Manjusha Gaglani, Lauren E.W. Olsho, Lauren Grant, Natasha Schaefer-Solle, Paola Louzado-Feliciano, Harmony L. Tyner, Sarang K. Yoon, Allison L. Naleway, Michael Smith, Brian E. Sokol, Karen Lutrick, Ashley L. Fowlkes, Jennifer Meece, Roger Noriega, Marilyn Odean, Andrew L. Phillips, Holly C. Groom, Kempapura Murthy, Laura J. Edwards, Katherine D. Ellingson, Young M. Yoo, Alexandra Cruz, Karley Respet, Matthew S. Thiese, Jennifer L. Kuntz, Spencer Rose, Louise S. Hadden, Joe K. Gerald, Josephine Mak, Damena Gallimore-Wilson, Jessica Lundgren, Kurt T. Hegmann, Kayan Dunnigan, Meredith G. Wesley, Edward J. Bedrick, Julie Mayo Lamberte, John M. Jones, Angela Hunt, Matthew M. Bruner, Kimberly Groover, Preeta K. Kutty, Addison Testoff, Lindsay B. LeClair, Jini N. Etolue, Mark G. Thompson, Jefferey L. Burgess
medRxiv 2021.11.24.21266396; doi: https://doi.org/10.1101/2021.11.24.21266396

Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
Tyll Krueger, Krzysztof Gogolewski, Marcin Bodych, Anna Gambin, Giulia Giordano, Sarah Cuschieri, Thomas Czypionka, Matjaz Perc, Elena Petelos, Magdalena Rosinska, Ewa Szczurek
medRxiv 2021.05.07.21256847; doi: https://doi.org/10.1101/2021.05.07.21256847 Revision

Is mandatory vaccination in population over 60 adequate to control the COVID-19 pandemic in E.U.?
N.P. Rachaniotis, T.K. Dasaklis, F. Fotopoulos, M. Chouzouris, V. Sypsa, A. Lyberaki, P. Tinios
medRxiv 2022.01.25.22269867; doi: https://doi.org/10.1101/2022.01.25.22269867 Revision

Understanding of and Trust in the Centers for Disease Control and Prevention’s Revised COVID-19 Isolation and Quarantine Guidance Among US Adults
Vishala Mishra, Joseph P. Dexter
medRxiv 2022.02.01.22270288; doi: https://doi.org/10.1101/2022.02.01.22270288

Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh
Md Mohsin, Sultan Mahmud, Ashraf Uddin Mian, Prottay Hasan, Abdul Muyeed, Ariful Islam, Maisha Maliha Rahman, Mahfuza Islam, Md Hasinur Rahaman Khan, M. Shafiqur Rahman
medRxiv 2022.01.31.22270172; doi: https://doi.org/10.1101/2022.01.31.22270172

Wellcome Open Research [to 05 Feb 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 05 Feb 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Study Protocol metrics AWAITING PEER REVIEW
Characterising and Addressing the Psychosocial Impact of Tuberculosis in Indonesia (CAPITA): A study protocol [version 1; peer review: awaiting peer review]
Ahmad Fuady, Agus Fitriangga, Agus Sugiharto, Bustanul Arifin, Ferdiana Yunita, Finny Fitry Yani, Helmi Suryani Nasution, I Wayan Gede Artawan Eka Putra, Saidah Rauf, Muchtaruddin Mansyur, Tom Wingfield
Peer Reviewers Invited
Funders
Wellcome Trust
Royal Society of Tropical Medicine and Hygiene
PUBLISHED 04 Feb 2022

Research Article metrics
Revised
10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity [version 3; peer review: 1 approved, 1 approved with reservations]
John W.G. Addy, Yaw Bediako, Francis M. Ndungu, John Joseph Valetta, Adam J. Reid, Jedida Mwacharo, Joyce Mwongeli Ngoi, Joshua Wambua, Edward Otieno, Jennifer Musyoki, Khadija Said, Matthew Berriman, Kevin Marsh, Philip Bejon, Mario Recker, Jean Langhorne
Peer Reviewers Rodrigo M Corder; Rhea J Longley
Funders
Wellcome Trust
Francis Crick Institute
Medical Research Council
LATEST VERSION PUBLISHED 04 Feb 2022

Research Article metrics AWAITING PEER REVIEW
“An increase in COVID-19 patients would be overwhelming”: A qualitative description of healthcare workers’ experiences during the first wave of COVID-19 (March 2020 to October 2020) at Malawi’s largest referral hospital. [version 1; peer review: awaiting peer review]
Felix Limbani, Blessings M Kapumba, Henry Mzinganjira, Tamara Phiri, Henry C Mwandumba, Jamie Rylance, Ben Morton, Nicola Desmond
Peer Reviewers Invited
Funder
Wellcome Trust
PUBLISHED 04 Feb 2022

Research Article metrics
Revised
Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-CoV-2 in hospitalised patients: a retrospective cohort study [version 2; peer review: 2 approved]
Thomas C. Williams, Elizabeth Wastnedge, Gina McAllister, Ramya Bhatia, Kate Cuschieri, Kallirroi Kefala, Fiona Hamilton, Ingólfur Johannessen, Ian F. Laurenson, Jill Shepherd, Alistair Stewart, Donald Waters, Helen Wise, Kate E. Templeton
Peer Reviewers James Otieno; Mariska M.G. Leeflang
Funder
Wellcome Trust
LATEST VERSION PUBLISHED 01 Feb 2022

Think Tanks
 
 
Brookings [to 05 Feb 2022]
http://www.brookings.edu/
Accessed 05 Feb 2022
Africa in Focus
Figure of the week: Vaccine inequity in Africa
Sakinatou Djantchiemo and Tamara White
Friday, February 4, 2022
 
 
Center for Global Development [to 05 Feb 2022]
https://www.cgdev.org/
Publications [Selected]
January 28, 2022
Decentralized Purchasing of Essential Medicines and Its Impact on Availability, Prices, and Quality: A Review of Current Evidence
Providing patients with high-quality essential medicines requires a well-functioning procurement, distribution, and regulatory system. However, in many low- and lower-middle-income countries (LMICs), public sector supply chain performance is far from optimal, resulting in frequent stockouts at health clinics. Decentralized purchasing of essential medicines by health facilities themselves provides greater autonomy to health facilities in managing their medicine stock, and has the potential to reduce essential medicine stockouts.
Lyudmila Nepomnyashchiy and Prashant Yadav
 
 
Chatham House [to 05 Feb 2022]
https://www.chathamhouse.org/
Accessed 05 Feb 2022
World in brief: AU-EU summit
African states on the front foot as they demand action
The World Today 4 February 2022
The sixth African Union-European Union summit taking place in mid-February faces a fresh set of challenges as the world emerges from the Covid pandemic.

Traditionally held every three years, the previous summit was in 2017 in Côte d’Ivoire with this sixth summit being postponed due to the pandemic.

The two-day conference in Brussels from February 17 will move forward the debate on vaccine production and licensing, as well as exploring the deepening concerns over debt financing, infrastructure, migration, climate and security in the Sahel.

The African continent has been hard hit by the pandemic, with World Bank figures showing levels of debt in sub-Saharan low to middle-income countries reaching $702 billion in 2020, the highest in a decade.

Recent complaints by Cyril Ramaphosa, South Africa’s president, of ‘vaccine apartheid’, along with similar grievances over Covid travel restrictions by other African leaders, have raised the temperature.
‘Covid is shaping the entire economic and political terrain of African states at the moment and there is a lot of bad blood,’ said Phil Clark, a professor of international politics at the School of Oriental and African Studies in London.

‘They are going to the summit with a fair amount of anger over how Europe has tackled Covid in Africa, and the EU will have their work cut out to move beyond that.’…

 
 
CSIS
https://www.csis.org/
Accessed 05 Feb 2022
Transcript
Covid-19 Vaccine Confidence at One Year
February 4, 2022
So I am particularly pleased to invite Heidi Larson, professor of anthropology, risk, and decision science, and director of The London School’s Vaccine Confidence Project, which she founded in 2010, to set the stage. Heidi is the author of the book “Stuck: How Vaccine Rumors Start and Why They Don’t Go Away,” which came out in the summer of 2020. Since 2015, she has been leading work on the Vaccine Confidence Index, which surveys vaccine attitudes in 60 to 70 countries. And this past December the BBC placed her on its prestigious 100 Women list, which last year highlighted those who are hitting reset, playing their part to reinvent our society, our culture, and our world.

Podcast Episode
Dr. Michael Osterholm: “Don’t Be Surprised When You Are Surprised.”
January 28, 2022 | By H. Andrew Schwartz, J. Stephen Morrison

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 05 Feb 2022
February 1, 2022 News Release
Vaccine Monitor: 6 in 10 Parents of Teens and One-Third of Parents of 5-11 Year-Olds Say Their Child is Vaccinated for COVID-19, Both Up Since November
1 in 4 Parents Say Their Student Had to Quarantine in January Due to COVID-19 Infection or Exposure; Overall 4 in 10 Report Some Education Disruption Growing shares of parents say that their eligible children have gotten at least one dose of a COVID-19 vaccine, and three in ten parents…
 
 
Rand [to 05 Feb 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Report
The U.S. Equity-First Vaccination Initiative: Early Insights
The Equity-First Vaccination Initiative aims to reduce racial/ethnic disparities in U.S. coronavirus vaccination rates. Five demonstration sites are using hyper-local, community-led strategies to increase vaccine confidence and access.
Jan 28, 2022
Laura J. Faherty, Jeanne S. Ringel, Malcolm V. Williams, Ashley M. Kranz, Lilian Perez, Lucy Schulson, Allyson D. Gittens, Brian Phillips, Lawrence Baker, Priya Gandhi, Khadesia Howell, Rebecca Wolfe, Tiwaladeoluwa Adekunle

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation,
Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.